Base-case cost-effectiveness analysis
| Strategy . | Base-case model . | PSA model . | ||||
|---|---|---|---|---|---|---|
| Cost, US$ . | Incremental cost, US$ . | Effectiveness, QALY . | Incremental effectiveness, QALY . | ICER, US$/QALY . | ICER 95% CI, $/QALY . | |
| Azacitidine-venetoclax | 491 093 | 159 595 | 1.53 | 0.61 | 260 343 | 187 731-532 313 |
| Azacitidine | 331 498 | — | 0.91 | — | — | — |
| Strategy . | Base-case model . | PSA model . | ||||
|---|---|---|---|---|---|---|
| Cost, US$ . | Incremental cost, US$ . | Effectiveness, QALY . | Incremental effectiveness, QALY . | ICER, US$/QALY . | ICER 95% CI, $/QALY . | |
| Azacitidine-venetoclax | 491 093 | 159 595 | 1.53 | 0.61 | 260 343 | 187 731-532 313 |
| Azacitidine | 331 498 | — | 0.91 | — | — | — |
CI, confidence interval; PSA, probabilistic sensitivity analysis.